AHA 2024: Plozasiran demonstrates promising Phase III results in FCS adults
During AHA 2024, data were presented from the Phase III trial of plozasiran targeting adults with genetically or clinically diagnosed FCS,
During AHA 2024, data were presented from the Phase III trial of plozasiran targeting adults with genetically or clinically diagnosed FCS,
What's Your Reaction?
